(Information sent by the signatory company)
– New challenge on board? Syai Health Brings New Fashion to CGM Experience and Chronic Disease Treatment
Syai Health secured significant funding from AstraZeneca plc and Xiaomi Corporation.
SINGAPORE, Feb. 21, 2024 /PRNewswire/ — Singapore-based biotech company Syai Health, short for “Sychronise AI”, has secured significant funding from leading investors such as AstraZeneca plc and Xiaomi Corporation for its internally developed medical devices powered by AI. Originally a spin-out from Oxford-Cambridge, together with an R&D team from leading institutions and a design team from the Royal College of Art, Syai Health achieved another crucial fundraising milestone after years of dedication. Driven by a strong belief in industry transformation (CDM), Syai’s cutting-edge products such as continuous glucose monitor promise to revolutionize home health management with next-level digitalization. Syai Health is set to broaden the horizon and reshape the CGM experience with its line of user-centric products powered by AI integration.
Syai has distinguished itself in the market for its careful design and data processing capabilities. The all-in-one monitoring unit can be worn discreetly on the body with a size of less than a quarter and a weight of only 1.6 g. Syai integrates its advanced algorithm that not only analyzes glucose readings in real time but also provides personalized feedback for reference, making the device a responsive and considerate companion in users’ health management process. It unlocked the potential for proactive users to make informed changes to their lifestyle and overall well-being.
Syai’s CGM device is combined with an easy-to-use app and cloud-based data solutions that allow patients to track, retrieve and share real-time data or reports with their healthcare providers or families for more comprehensive care. . Syai transformatively positioned data at the core of its CDM strategy, where data-driven analytics and deep learning help improve quality of life, marking a major milestone for Syai Health.
Syai is set to expand its reach and make its CGM devices available to global customers with the financing. The company’s success in acquiring the aforementioned investment is a testament to its prospects for growth and innovation. Looking at the rising trends in personal care and people’s wellness management in recent years, Syai’s medical devices with advanced software systems are well positioned to capture a significant share of the target market and revitalize CDM experiences. (Chronic Disease Management) for clients worldwide.
About Syai
Based in Singapore, Syai Health has become the transcendent of CDM. For more information, visit: http://www.syai. com
For media/business enquiries, contact: bd@syai.com
Photo – https://mma.prnewswire.com/media/2343276…
View original content: https://www.prnewswire.com/news-releases/syai-health-aporta-la-nueva-moda-a-la-experiencia-cgm-y-al-tratamiento-de-enfermedades-cronicas-302066777.html
